Home Page
News Coverage
Proneuron Biotechnologies: Treatment for Spinal Cord Injury and other Neurological Disorders
Home Page
       Clinical Studies
      News & Events

Date: October 5th, 2010
Title: Israeli High Court of Justice Rules Proneuron can sue Teva

Israel's High Court of Justice has accepted an appeal by Proneuron Biotechnologies Inc. that its legal proceedings against Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA) will not be delayed in favor of arbitration proceedings.

Full story

Date: October 15th, 2009
Title: Israeli Supreme Court Rejects Teva Appeal

The Israeli Supreme Court rejected an appeal by Teva Pharmaceutical Industries Ltd. (Nasdaq: Teva; TASE: TEVA) and agreed to hear the dispute between Teva and Proneuron Biotechnologies Inc. In its ruling, the court stated that there is a significant public interest to conduct this case in open doors and keep it in Israel.

Full story

Date: January 21, 2009
Title: Proneuron announces an award from the U.S. Army Medical Research Institute of Chemical Defense

Proneuron Biotechnologies, Inc. announced that it has obtained a grant from the US Government to develop the molecule Poly-YE as a neuroprotective vaccine against brain damage following exposure to nerve gas intoxication. So far, Proneuronís study has proved that Poly-YE has a long-term beneficial effect on functional recovery in cases of central nervous system damage when the treatment is appropriately administered.

Full story

Date: July 14th, 2008
Title: Proneuron Alleges Unfair Co-Licensing Behavior by Teva

Teva Pharmaceuticals, the marketer and producer of Copaxone (glatiramer acetate) is being investigated by Israel's Ministry of Health for the company's study of Copaxone in patients with Amytrophic Lateral Sclerosis (ALS)

Full story

Date: January 24, 2007
Title: Proneuron Announces the Receipt of a $430,000 Grant from the Michael J. Fox Foundation to Develop Its PN277 for the Treatment of Parkinson's Disease 

Full story

Disclaimer | Site Map | Home Page| Contact Us

Proneuron Biotechnologies is engaged in research
related to spinal cord injuries and paralysis cure.

Top of page Print this page